National Guideline Clearinghouse | Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70).

National Institute for Health and Clinical Excellence (NICE) ► full-text:
National Guideline Clearinghouse | Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70).

Guideline Title

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70).

 

 

Bibliographic Source(s)

National Institute for Health and Clinical Excellence (NICE). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Apr. 74 p. (Technology appraisal guidance; no. 251).

 

 

Guideline Status

This is the current release of the guideline.
This guideline updates a previous version: National Institute for Clinical Excellence (NICE). Guidance on the use of imatinib for chronic myeloid leukaemia. London (UK): National Institute for Clinical Excellence (NICE); 2003 Oct. 26 p. (Technology appraisal; no. 70).